FLASCO

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Non-Small Cell Lung Cancer

  • FLASCO
  • October 27, 2016

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Non-Small Cell Lung Cancer. These NCCN Guidelines® are currently available as Version 2.2017. 

  • Metastatic Disease (NSCL-17)
    • Testing results modified for PD-L1: PD-L1 positive and EGFR, ALK, ROS1 negative or unknown
  • Subsequent Therapy (NSCL-24)
    • PS 0-2: Atezolizumab added as a treatment option. Reference added: Barlesi F, Park K, Ciardiello F, et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC [abstract]. ESMO Congress; Copenhagen. ESMO 2016:LBA44.
    • Erlotinib removed as a treatment option in subsequent therapy and maintenance therapy.
    • Footnote “ww” modified: Pembrolizumab is approved for patients with NSCLC tumors with PD-L1 expression levels ≥1%, as determined by an FDA-approved test.
    • Footnote “aaa” modified: If not already given, options for PS 0-2 include (nivolumab, pembrolizumab, or atezolizumab), docetaxel (category 2B), pemetrexed (category 2B), gemcitabine (category 2B), or ramucirumab + docetaxel (category 2B); options for PS 3-4 include best supportive care. Options for further progression are best supportive care or clinical trial.
  • Subsequent Therapy (NSCL-25)
    • PS 0-2: Atezolizumab added as a treatment option. Reference added: Barlesi F, Park K, Ciardiello F, et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC [abstract]. ESMO Congress; Copenhagen. ESMO 2016:LBA44.
    • Footnote “ww” modified: Pembrolizumab is approved for patients with NSCLC tumors with PD-L1 expression levels ≥1%, as determined by an FDA-approved test.
    • Footnote “bbb” modified: If not already given, options for PS 0-2 include (nivolumab, pembrolizumab, or atezolizumab), docetaxel (category 2B), gemcitabine (category 2B), or ramucirumab + docetaxel (category 2B); options for PS 3-4 include best supportive care. Options for further progression are best supportive care or clinical trial.

Who’s Online

There are no users currently online